Showing results (471-480 of 532) with videos related to

Sort By:
Pageof 54
The Science of the Total Environment|April 8, 2025
Cataloging olive oil mill wastewater sludge based on toxicological profiles and functional microbial diversityM R Martínez-Gallardo, R Jiménez, F Suárez-Estrella, et al.
Antiviral Therapy|December 4, 2014
Impact of IL28B genotype on first-week response to telaprevir-based therapy in HIV-HCV coinfectionKarin Neukam, Daniela Munteanu, Sebastian Haubitz, et al.
Infection|August 9, 2013
Evaluation of an infectious disease consultation programme in a German tertiary care hospitalJ J Vehreschild, G Morgen, O A Cornely, et al.
BMC Infectious Diseases|December 1, 2019
Meningitis gone viral: description of the echovirus wave 2013 in GermanyJonas Graf, Christian J Hartmann, Helmar C Lehmann, et al.
Journal of Hepatology|February 24, 2009
Insulin resistance is not a relevant predictor of sustained virological response to pegylated interferon plus ribavirin in HIV/HCV co-infected patientsNicolás Merchante, Ignacio de los Santos-Gil, Dolores Merino, et al.
Hepatology (Baltimore, Md.)|August 12, 2009
Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virusJuan Macías, Juan Berenguer, Miguel A Japón, et al.
Plos One|February 6, 2016
Liver Toxicity of Current Antiretroviral Regimens in HIV-Infected Patients with Chronic Viral Hepatitis in a Real-Life Setting: The HEPAVIR SEG-HEP CohortKarin Neukam, José A Mira, Antonio Collado, et al.
Frontiers in Pharmacology|November 21, 2022
Glia from the central and peripheral nervous system are differentially affected by paclitaxel chemotherapy via modulating their neuroinflammatory and neuroregenerative propertiesInes Klein, Janne Boenert, Felix Lange, et al.
Antiviral Therapy|August 3, 2007
Rapid virological response at week 4 predicts response to pegylated interferon plus ribavirin among HIV/HCV-coinfected patientsJosé A Mira, Bárbara Valera-Bestard, Ana Arizcorreta-Yarza, et al.
The Journal of Antimicrobial Chemotherapy|September 10, 2011
Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patientsKarin Neukam, José A Mira, Josefa Ruiz-Morales, et al.
Pageof 54